{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:44:33Z","timestamp":1791204273587,"version":"4.2.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WO 1746\/5-1"],"award-info":[{"award-number":["WO 1746\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cmi.2025.04.027","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:04:30Z","timestamp":1745899470000},"page":"1475-1483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Target trial emulation framework: mitigating methodological challenges and application in COVID-19 treatment evaluation studies"],"prefix":"10.1016","volume":"31","author":[{"given":"Oksana","family":"Martinuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"le Cessie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolkewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.04.027_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pds.5632","article-title":"Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19","volume":"32","author":"Hempenius","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cmi.2025.04.027_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cmi.2021.03.003","article-title":"Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness","volume":"27","author":"Martinuka","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"Sp. 2","key":"10.1016\/j.cmi.2025.04.027_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7705\/biomedica.5987","article-title":"Escollos y peligros del an\u00e1lisis de supervivencia bajo supuestos incorrectos: El caso de los datos de COVID-19 [Pitfalls and perils of survival analysis under incorrect assumptions: The case of COVID-19 data]","volume":"41","author":"Piovani","year":"2021","journal-title":"Biomedica"},{"key":"10.1016\/j.cmi.2025.04.027_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/EDE.0000000000001598","article-title":"Effectiveness of remdesivir treatment protocols among patients hospitalized with COVID-19: A target trial emulation","volume":"34","author":"Breskin","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.cmi.2025.04.027_bib6","article-title":"Molnupiravir and risk of hospital admission or death in adults with covid-19: Emulation of a randomized target trial using electronic health records","volume":"380","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib7","article-title":"Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: Comparative effectiveness study","volume":"377","author":"Urner","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib8","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: A framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.04.027_bib9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: What, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2025.04.027_bib10","series-title":"Confounding \u2013 Structure. Wiley StatsRef: Statistics Reference Online","author":"Hern\u00e1n","year":"2019"},{"key":"10.1016\/j.cmi.2025.04.027_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/sim.70009","article-title":"Inverse probability of treatment weighting using the propensity score with competing risks in survival analysis","volume":"44","author":"Austin","year":"2025","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/aje\/kwab028","article-title":"Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: Designing real-world evidence studies","volume":"190","author":"Renoux","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib14","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.04.027_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/sim.7215","article-title":"Accounting for competing risks in randomized controlled trials: A review and recommendations for improvement","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/CLEP.S256735","article-title":"Statistical analysis of clinical COVID-19 data: A concise overview of lessons learned, common errors and how to avoid them","volume":"12","author":"Wolkewitz","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.cmi.2025.04.027_bib63","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib17","article-title":"Bias by censoring for competing events in survival analysis","volume":"378","author":"Coemans","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib18","doi-asserted-by":"crossref","first-page":"106758","DOI":"10.1016\/j.cct.2022.106758","article-title":"Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials","volume":"119","author":"Li","year":"2022","journal-title":"Contemp Clin Trial."},{"key":"10.1016\/j.cmi.2025.04.027_bib19","doi-asserted-by":"crossref","first-page":"106144","DOI":"10.1016\/j.ijantimicag.2020.106144","article-title":"Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: A nationwide observational study of 8075 participants","volume":"56","author":"Catteau","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.027_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: A nonmathematical illustration of competing risk analysis","volume":"122","author":"Schuster","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib21","first-page":"210","article-title":"Informative censoring-A cause of bias in estimating COVID-19 mortality using hospital data","volume":"13","author":"Lin","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cmi.2025.04.027_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jclinepi.2016.07.013","article-title":"Competing risk bias was common in a prominent medical journal","volume":"80","author":"Schumacher","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib23","article-title":"Methodological biases in observational hospital studies of COVID-19 treatment effectiveness: Pitfalls and potential","volume":"11","author":"Martinuka","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cmi.2025.04.027_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib25","article-title":"Emulierung von \u201ctarget trials\u201d mit Real-world-Daten","author":"Braitmaier","year":"2022","journal-title":"Pr\u00e4v Gesundheitsf"},{"key":"10.1016\/j.cmi.2025.04.027_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: Why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib27","series-title":"Causal inference: What if","author":"Hernan","year":"2024"},{"key":"10.1016\/j.cmi.2025.04.027_bib28","article-title":"Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): Considerations from the FDA Sentinel Innovation Center","volume":"384","author":"Desai","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib29","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: Trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib30","article-title":"Ideal trials, target trials and actual randomized trials","author":"Moreno-Betancur","year":"2024","journal-title":"arXiv"},{"key":"10.1016\/j.cmi.2025.04.027_bib31","doi-asserted-by":"crossref","first-page":"1380568","DOI":"10.3389\/fdsfr.2024.1380568","article-title":"Application of the target trial emulation framework to external comparator studies","volume":"4","author":"Arnold","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.cmi.2025.04.027_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305467","article-title":"Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis","volume":"19","author":"Rivera","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2025.04.027_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ckj\/sfaa242","article-title":"Pharmacoepidemiology for nephrologists (part 2): Potential biases and how to overcome them","volume":"14","author":"Fu","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cmi.2025.04.027_bib34","article-title":"Target trial emulation: Applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib35","article-title":"How to estimate the effect of treatment duration on survival outcomes using observational data","volume":"360","author":"Hern\u00e1n","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies","volume":"96","author":"Danaei","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: Foundations and methodological implementation","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.cmi.2025.04.027_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamainternmed.2024.8129","article-title":"Emulating a target trial using observational data","volume":"185","author":"Dib","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib40","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/pds.5612","article-title":"Design considerations for observational studies of drugs for advanced cancer","volume":"32","author":"Garcia-Albeniz","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cmi.2025.04.027_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/ije\/dyaa225","article-title":"Reply to: Versatility of the clone-censor-weight approach: Response to \u201ctrial emulation in the presence of immortal-time bias\u201d","volume":"50","author":"Maringe","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib43","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ije\/dyaa223","article-title":"Versatility of the clone-censor-weight approach: Response to \u201ctrial emulation in the presence of immortal-time bias\u201d","volume":"50","author":"Zhao","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cmi.2022.09.002","article-title":"Observational vs. randomized controlled trials to inform antibiotic treatment durations: A narrative review","volume":"29","author":"McDonald","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.027_bib45","series-title":"Biostatistics in biopharmaceutical research and development","first-page":"53","article-title":"Statistical methods for accommodating immortal time: A selective review and comparison","author":"Wang","year":"2024"},{"key":"10.1016\/j.cmi.2025.04.027_bib46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/EDE.0000000000001601","article-title":"Emulating target trials to avoid immortal time bias - An application to antibiotic initiation and preterm delivery","volume":"34","author":"Caniglia","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.cmi.2025.04.027_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1164\/rccm.202111-2495OC","article-title":"Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: An emulated target trial analysis","volume":"206","author":"Hajage","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib48","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1164\/rccm.202008-3238CP","article-title":"Attention to immortal time bias in critical care research","volume":"203","author":"Vail","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib49","series-title":"Developing a protocol for observational comparative effectiveness research: A user\u2019s guide. AHRQ Publication No. 12(13)-EHC099","year":"2013"},{"key":"10.1016\/j.cmi.2025.04.027_bib50","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib51","article-title":"The estimands framework: A primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.027_bib52","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/aje\/kwad090","article-title":"Considering questions before methods in dementia research with competing events and causal goals","volume":"192","author":"Rojas-Saunero","year":"2023","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0962280216628900","article-title":"Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator","volume":"27","author":"Willems","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.cmi.2025.04.027_bib54","doi-asserted-by":"crossref","first-page":"e1322","DOI":"10.1212\/WNL.0000000000010433","article-title":"Emulating a target trial of statin use and risk of dementia using cohort data","volume":"95","author":"Caniglia","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2025.04.027_bib55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.5811\/westjem.2018.4.38383","article-title":"Understanding the use of composite endpoints in clinical trials","volume":"19","author":"McCoy","year":"2018","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib56","article-title":"Target trial emulation using hospital-based observational data: Demonstration and application in COVID-19","volume":"13","author":"Martinuka","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cmi.2025.04.027_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12874-023-02000-9","article-title":"Implementation of the trial emulation approach in medical research: A scoping review","volume":"23","author":"Scola","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2025.04.027_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jclinepi.2023.08.003","article-title":"The implementation of target trial emulation for causal inference: A scoping review","volume":"162","author":"Zuo","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086595","article-title":"Conducting observational analyses with the target trial emulation approach: A methodological systematic review","volume":"14","author":"Simon-Tillaux","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2025.04.027_bib60","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1002\/sim.8741","article-title":"Formulating causal questions and principled statistical answers","volume":"39","author":"Goetghebeur","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2025.04.027_bib61","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/aje\/kwab040","article-title":"Emulating target trials to improve causal inference from agent-based models","volume":"190","author":"Murray","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2025.04.027_bib62","doi-asserted-by":"crossref","first-page":"101473","DOI":"10.1016\/j.beha.2023.101473","article-title":"What should be done and what should be avoided when comparing two treatments?","volume":"36","author":"Brion Bouvier","year":"2023","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:50:25Z","timestamp":1758664225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1198743X25001909"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.027","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target trial emulation framework: mitigating methodological challenges and application in COVID-19 treatment evaluation studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}